Geron Corp (GERN), Janssen Pharma Enter Exclusive Licensing Agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Futures tread higher as Alphabet, Microsoft results lift megacaps
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- Alphabet, Microsoft and Snap rise premarket; Intel, Hertz Global fall
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
FBR Capital Reiterates Outperform on Geron Corp (GERN) Following Disclosed License Agreement
September 19, 2016 10:09 AM EDTFBR Capital reiterated an Outperform rating and $5.00 price target on Geron Corporation (NASDAQ: GERN) as the company's SEC filing disclosed that Geron Corporation and Janssen Pharmaceuticals, Inc. signed a license agreement. The agreement grants exclusive rights of GERN patients and know-how related to oligonucleotide backbone chemistry and RNAi.
Analyst Thomas Yip commented, "On the... More
